Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.

Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P.

J Patient Rep Outcomes. 2019 Oct 26;3(1):64. doi: 10.1186/s41687-019-0153-y.

2.

Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin.

Ervin C, Joish VN, Evans E, DiBenedetti D, Reaney M, Preblick R, Castro R, Danne T, Buse JB, Lapuerta P.

Clin Ther. 2019 Nov;41(11):2219-2230.e6. doi: 10.1016/j.clinthera.2019.09.003. Epub 2019 Oct 3.

PMID:
31587812
3.

Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.

Joish VN, Perez-Olle R, Lapuerta P, Dharba S, Zacks J.

Clin Ther. 2019 Sep;41(9):1716-1723.e2. doi: 10.1016/j.clinthera.2019.06.013. Epub 2019 Jul 17.

PMID:
31326125
4.

TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.

Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB.

Oncologist. 2019 Nov;24(11):1446-1452. doi: 10.1634/theoncologist.2018-0921. Epub 2019 Jun 12.

5.

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.

Joish VN, Shah S, Tierce JC, Patel D, McKee C, Lapuerta P, Zacks J.

Future Oncol. 2019 Apr;15(12):1397-1406. doi: 10.2217/fon-2018-0960. Epub 2019 Feb 8.

6.

Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.

Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W.

Oncologist. 2019 Aug;24(8):e662-e670. doi: 10.1634/theoncologist.2018-0236. Epub 2019 Jan 16.

PMID:
30651397
7.

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR.

Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH.

Clin Ther. 2018 Dec;40(12):2006-2020.e2. doi: 10.1016/j.clinthera.2018.10.008. Epub 2018 Nov 24.

8.

In Reply: Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.

Jiang W, Perez-Olle R, Lapuerta P.

Pancreas. 2018 Oct;47(9):e57. doi: 10.1097/MPA.0000000000001138. No abstract available.

9.

Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.

Burton T, Lapuerta P.

Future Oncol. 2018 Oct;14(23):2361-2370. doi: 10.2217/fon-2018-0129. Epub 2018 Aug 10.

PMID:
30095284
10.

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.

Danne T, Cariou B, Banks P, Brandle M, Brath H, Franek E, Kushner JA, Lapuerta P, McGuire DK, Peters AL, Sawhney S, Strumph P.

Diabetes Care. 2018 Sep;41(9):1981-1990. doi: 10.2337/dc18-0342. Epub 2018 Jun 24.

PMID:
29937431
11.

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.

Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P.

Diabetes Care. 2018 Sep;41(9):1970-1980. doi: 10.2337/dc18-0343. Epub 2018 Jun 24.

12.

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.

Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH.

Clin Ther. 2018 Jun;40(6):952-962.e2. doi: 10.1016/j.clinthera.2018.04.006. Epub 2018 May 1.

13.

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, Garcia-Carbonero R.

Endocr Relat Cancer. 2018 Mar;25(3):309-322. doi: 10.1530/ERC-17-0455. Epub 2018 Jan 12.

14.

Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.

Joish VN, Frech F, Lapuerta P.

Clin Ther. 2017 Dec;39(12):2338-2344. doi: 10.1016/j.clinthera.2017.10.019. Epub 2017 Nov 23.

PMID:
29175096
15.

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.

Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB.

Clin Ther. 2017 Nov;39(11):2158-2168. doi: 10.1016/j.clinthera.2017.09.013. Epub 2017 Oct 23.

16.

Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.

Joish VN, Frech F, Lapuerta P.

J Med Econ. 2018 Feb;21(2):182-188. doi: 10.1080/13696998.2017.1387120. Epub 2017 Oct 9.

PMID:
28959913
17.

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.

Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, Pozzilli P, Gesty-Palmer D, Lapuerta P, Simó R, Danne T, McGuire DK, Kushner JA, Peters A, Strumph P.

N Engl J Med. 2017 Dec 14;377(24):2337-2348. doi: 10.1056/NEJMoa1708337. Epub 2017 Sep 13.

18.

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.

Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, Pavel M.

J Clin Oncol. 2017 Jan;35(1):14-23. Epub 2016 Oct 28.

PMID:
27918724
19.

Reply: High Risk of Gastrointestinal Bleeding on Dual Antiplatelet Treatment.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Aug 30;68(9):981-2. doi: 10.1016/j.jacc.2016.06.008. No abstract available.

20.

Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.

Vaduganathan M, Cannon CP, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Bhatt DL; COGENT Investigators.

Am J Med. 2016 Sep;129(9):1002-5. doi: 10.1016/j.amjmed.2016.03.042. Epub 2016 Apr 30.

PMID:
27143321
21.

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach.

Gelhorn HL, Kulke MH, O'Dorisio T, Yang QM, Jackson J, Jackson S, Boehm KA, Law L, Kostelec J, Auguste P, Lapuerta P.

Clin Ther. 2016 Apr;38(4):759-68. doi: 10.1016/j.clinthera.2016.03.002. Epub 2016 Mar 31.

22.

Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.

Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP; COGENT Investigators.

J Am Coll Cardiol. 2016 Apr 12;67(14):1661-71. doi: 10.1016/j.jacc.2015.12.068. Epub 2016 Mar 21.

23.

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.

Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P.

Diabetes Care. 2015 Jul;38(7):1181-8. doi: 10.2337/dc14-2806. Epub 2015 Jun 6.

24.

The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.

Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL.

Aliment Pharmacol Ther. 2015 Aug;42(3):365-74. doi: 10.1111/apt.13260. Epub 2015 May 29.

25.

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.

Lapuerta P, Zambrowicz B, Strumph P, Sands A.

Diab Vasc Dis Res. 2015 Mar;12(2):101-10. doi: 10.1177/1479164114563304. Review.

PMID:
25690134
26.

Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial.

Pavel M, Hörsch D, Caplin M, Ramage J, Seufferlein T, Valle J, Banks P, Lapuerta P, Sands A, Zambrowicz B, Fleming D, Wiedenmann B.

J Clin Endocrinol Metab. 2015 Apr;100(4):1511-9. doi: 10.1210/jc.2014-2247. Epub 2015 Jan 30.

PMID:
25636046
27.

LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.

Zambrowicz B, Lapuerta P, Strumph P, Banks P, Wilson A, Ogbaa I, Sands A, Powell D.

Clin Ther. 2015 Jan 1;37(1):71-82.e12. doi: 10.1016/j.clinthera.2014.10.026. Epub 2014 Dec 17.

PMID:
25529979
28.

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.

Rosenstock J, Cefalu WT, Lapuerta P, Zambrowicz B, Ogbaa I, Banks P, Sands A.

Diabetes Care. 2015 Mar;38(3):431-8. doi: 10.2337/dc14-0890. Epub 2014 Sep 11.

29.

Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.

Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A.

Endocr Relat Cancer. 2014 Oct;21(5):705-14. doi: 10.1530/ERC-14-0173. Epub 2014 Jul 10.

30.

Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy.

Lapuerta P, Rosenstock J, Zambrowicz B, Powell DR, Ogbaa I, Freiman J, Cefalu WT, Banks P, Frazier K, Kelly M, Sands A.

Clin Cardiol. 2013 Jul;36(7):367-71. doi: 10.1002/clc.22125. Epub 2013 Apr 29.

31.

Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment.

Clerx L, van Rossum IA, Burns L, Knol DL, Scheltens P, Verhey F, Aalten P, Lapuerta P, van de Pol L, van Schijndel R, de Jong R, Barkhof F, Wolz R, Rueckert D, Bocchetta M, Tsolaki M, Nobili F, Wahlund LO, Minthon L, Frölich L, Hampel H, Soininen H, Visser PJ.

Neurobiol Aging. 2013 Aug;34(8):2003-13. doi: 10.1016/j.neurobiolaging.2013.02.002. Epub 2013 Mar 27.

32.

Incidence of serious upper and lower gastrointestinal events in older adults with and without Alzheimer's disease.

Wu JH, Guo Z, Kumar S, Lapuerta P.

J Am Geriatr Soc. 2011 Nov;59(11):2053-61. doi: 10.1111/j.1532-5415.2011.03667.x. Epub 2011 Oct 21.

PMID:
22091628
33.

Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation.

Budd D, Burns LC, Guo Z, L'italien G, Lapuerta P.

Clinicoecon Outcomes Res. 2011;3:189-95. doi: 10.2147/CEOR.S22265. Epub 2011 Oct 7.

34.

Clopidogrel with or without omeprazole in coronary artery disease.

Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP; COGENT Investigators.

N Engl J Med. 2010 Nov 11;363(20):1909-17. doi: 10.1056/NEJMoa1007964. Epub 2010 Oct 6.

35.

Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.

Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S.

Clin Exp Hypertens. 2009 Oct;31(7):572-84. doi: 10.3109/10641960902929420.

PMID:
19886855
36.
37.

The clinically meaningful change in physical performance scores in an elderly cohort.

Nieves JW, Li T, Zion M, Gussekloo J, Pahor M, Bernabei R, Simon H, Williams GR, Lapuerta P.

Aging Clin Exp Res. 2007 Dec;19(6):484-91.

PMID:
18172371
38.

The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.

Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P.

J Clin Hypertens (Greenwich). 2007 Dec;9(12 Suppl 5):23-30.

40.

A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.

Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A.

J Hum Hypertens. 2008 Apr;22(4):266-74. Epub 2007 Oct 11.

PMID:
17928878
41.

Regional variation in health care utilization and outcomes in ischemic stroke.

Williams LS, Eckert GJ, L'italien GJ, Lapuerta P, Weinberger M.

J Stroke Cerebrovasc Dis. 2003 Nov-Dec;12(6):259-65.

PMID:
17903937
42.

Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.

Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P.

J Clin Hypertens (Greenwich). 2006 Dec;8(12):850-7; quiz 858-9.

43.

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.

PMID:
17076969
44.

Walking speed predicts health status and hospital costs for frail elderly male veterans.

Purser JL, Weinberger M, Cohen HJ, Pieper CF, Morey MC, Li T, Williams GR, Lapuerta P.

J Rehabil Res Dev. 2005 Jul-Aug;42(4):535-46.

45.

[Adherence to guidelines in CHF therapy in Germany].

Flesch M, Komajda M, Lapuerta P, Hermans N, Le Pen C, Gonzáles-Juanatey JR, Van Veldhuisen DJ, Tavazzi L, Poole-Wilson P, Erdmann E.

Dtsch Med Wochenschr. 2005 Sep 30;130(39):2191-7. German.

PMID:
16189755
46.

Evaluation of continuous summary physical performance scores (CSPPS) in an elderly cohort.

Nieves JW, Zion M, Pahor M, Bernabei R, Gussekloo J, Simon H, Park JS, Li T, Lapuerta P, Williams GR.

Aging Clin Exp Res. 2005 Jun;17(3):193-200.

PMID:
16110731
47.

Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey.

Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson P, Le Pen C.

Eur Heart J. 2005 Aug;26(16):1653-9. Epub 2005 Apr 12.

PMID:
15827061
48.

Quality of care for hypertension in the United States.

Asch SM, McGlynn EA, Hiatt L, Adams J, Hicks J, DeCristofaro A, Chen R, LaPuerta P, Kerr EA.

BMC Cardiovasc Disord. 2005 Jan 7;5(1):1.

49.

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

Palmer AJ, Annemans L, Roze S, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, De Alvaro F.

Kidney Int Suppl. 2005 Jan;(93):S52-4.

PMID:
15613069
50.

A clinically meaningful difference was generated for a performance measure of recovery from hip fracture.

Hawkes WG, Williams GR, Zimmerman S, Lapuerta P, Li T, Orwig D, Wehren L, Hebel JR, Magaziner J.

J Clin Epidemiol. 2004 Oct;57(10):1019-24.

PMID:
15528052

Supplemental Content

Loading ...
Support Center